2026-01-13 - Analysis Report
**Financial Report for Johnson & Johnson (JNJ)**

### Company Overview
Johnson & Johnson is a multinational healthcare company that develops and manufactures medical devices, pharmaceuticals, and consumer packaged goods.

### Return Rate Comparison
* Cumulative Return of Review Stock (JNJ): 54.09%
* Cumulative Return of Comparison Stock (S&P 500, VOO): 94.34%
* Divergence: -43.80, Relative Divergence: 24.60%
* Degree of Divergence on the Last Day of the Data: -43.80

### Alpha, Beta Analysis
| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|-----|-------|------|-------|
| 2016-2018 | 6.0% | 16.8% | 3.0% | 0.7 | 310.9B |
| 2017-2019 | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020 | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021 | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022 | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023 | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024 | -30.0% | 13.8% | -50.0% | 0.2 | 348.4B |
| 2023-2025 | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

### Stock Price Fluctuations
* Close: $209.72
* Last-Market: $209.72 ($204.39, +2.61)
* 5-day SMA: $206.43
* 20-day SMA: $207.69
* 60-day SMA: $200.29

### RSI, PPO Indicators and Delta_Previous_Relative_Divergence
* Market Risk Indicator (MRI): 0.80 (High Investment Recommended)
* RSI: 58.19
* PPO: -0.20
* Hybrid Signal: Buy (Cash 0%)
* Recent (20 days) relative divergence change: -6.80 (worsening)
* 7-day Rank change: -3 (rank down)
* 7-day Dynamic Expected Return change: -22.70 (worsening)
* Expected Return (%): -74.90%

### Recent News & Significant Events
* Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead
* Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs
* Johnson & Johnson $JNJ Shares Sold by Atwater Malick LLC
* Assessing Johnson & Johnson (JNJ) Valuation After Drug Pricing Deal And New Clinical Trial Results
* More Upside For JNJ Stock In 2026?
* J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort

### Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): $212.00 / $240.00 / $155.00

### Recent Earnings Analysis
| Date | EPS | Revenue |
|-----|---:|--------|
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

### Financial Information
#### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

#### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

### Comprehensive Analysis
* Company overview: Johnson & Johnson is a multinational healthcare company.
* Return rate comparison: the company's cumulative return is lower than the comparison stock, with a degree of divergence of -43.80.
* Alpha, beta analysis: the company's Alpha and Beta values show varying trends over different periods.
* Stock price fluctuations: the stock's price has shown sharp rebounds and declines in recent periods.
* RSI, PPO indicators: the RSI value of 58.19 indicates a neutral trend, while the PPO value of -0.20 suggests a bearish trend.
* Recent news & significant events: the company has made progress in new clinical trials and partnerships, leading to increased stock performance.
* Analyst opinions: a buy consensus with a target price of $212.00.
* Recent earnings analysis: the company's EPS and revenue values show varying trends over different periods.
* Financial information: the company's revenue, profit margin, equity, and ROE values show varying trends over different periods.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.